MYOV - Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
- Supplemental New Drug Application of MYFEMBREE for pain associated with endometriosis has been submitted to FDA; PDUFA date of May 6, 2022 has been set.
- If FDA approval of MYFEMBREE for pain associated with endometriosis is achieved, then Myovant would be eligible to earn $100 million as a milestone payment from Pfizer.
- CHMP has given positive opinion for ORGOVYX for treatment of hormone-sensitive prostate cancer; European opinion expected mid 2022.
- The endometriosis sector across the seven major markets is expected to grow to $2.91 billion by 2030.
For further details see:
Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play